Simple Summary Surgical candidacy in the treatment of pancreatic cancer is complex. There
are multiple factors influencing if a patient is a good candidate for surgery with or without …

Pancreatic ductal adenocarcinoma (PDA) is the most common pancreatic malignancy,
comprising approximately 85% of cases. In 2009, it is estimated that more than 34,000 …

Objective: To identify objective preoperative prognostic factors that are able to predict long-
term survival of patients affected by PDAC. Summary of Background Data: In the modern era …

The last two decades have witnessed significant advances in surgical techniques and
systemic therapy, accompanied by a more nuanced understanding of the biological diversity …

Oncological pancreatic surgery requires a deep knowledge of multimodal treatment,
accurate preoperative recognition of tumor extension—especially to adjacent major vessels …

Simple Summary Pancreatic cancer remains one of the most dreaded cancers worldwide.
The incidence of this relatively rare cancer is increasing by almost 1.0% per year. It is …

Despite recent advances in the systemic treatment of gastrointestinal tumors, pancreatic
adenocarcinoma (PDAC) remains a challenging disease, with 5‐year survival just over 10 …

Background Locally advanced unresectable pancreatic cancer (LAPC) historically portends
a poor prognosis. FOLFIRINOX and gemcitabine/nab-paclitaxel have proven effective in the …

Background The guidelines for the classification of the resectability of pancreatic cancer
established by the National Comprehensive Cancer Network can be difficult to utilize in …

Objective To quantitatively assess the probability of tumor resection based on
measurements of tumor contact with the major peripancreatic vessels. Methods This is a …